The prodromal phase
Most patients with schizophrenia experience a period of disturbance before the onset of florid psychotic symptoms, which has come to be called the prodromal phase. Typically, the prodrome is characterised by nonspecific mood and anxiety symptoms, negative symptoms (such as poor drive, low energy and poor interpersonal skills) and attenuated positive symptoms (e.g. hallucinations and odd thinking). 5 More often than not, there is marked deterioration in social and occupational functioning. 6 Owing to its insidious nature, however, the prodrome is commonly only identified retrospectively at the onset of psychosis. Recently, a number of researchers have tried to identify the prodrome premorbidly in young people seeking medical assistance. [7] [8] [9] [10] [11] Accurate identification of patients during the prodromal phase may allow opportunities for intervention before the onset of psychosis. This is important in the context of the 'critical period hypothesis', which emphasises the importance of early intervention as a means of minimising further deterioration in function, and optimising outcome. 12 However, identification of the prodrome is not straightforward as symptoms are nonspecific, and many young people seem to experience quasi-psychotic symptoms without going on to develop schizophrenia. 5 This raises important ethical concerns regarding prodromal phase interventions. As the prodromal period at this point can only truly be identified in retrospect, we need to be cautious in identifying candidates for early intervention. The concerns raised include stigma, confidentiality and issues of autonomy. There is also a risk of committing falsely positive individuals to long-term treatment. 13 These ethical concerns have been addressed at specialised early psychosis centres. 14 however, there is a high rate of relapse within a few years.
It is therefore important that we continue to seek improved relapse prevention strategies. There has also been a resurgence of interest in psychosocial risk factors for the development of schizophrenia in the recent literature.
We review the literature on first-episode psychosis and highlight the significant findings.
of psychosis and deteriorating social function. 15 When these criteria are applied to young people seeking help, they are effective in identifying the majority of patients likely to develop a first episode of psychosis within a year. 16 Unfortunately, there are many people who develop schizophrenia without meeting these criteria.
Accompanying the development of early diagnostic criteria is a renewed focus on therapeutic interventions in first-episode psychosis. These interventions are aimed at treating the presenting symptoms as well as delaying or even preventing the onset of psychosis. There are now a number of specialised early psychosis centres around the world that use a multidisciplinary, holistic approach to prodromal interventions. [7] [8] [9] [10] [11] Individual elements of these interventions have been studied.
For example, several studies demonstrate that treatment with low doses of the second-generation antipsychotics olanzapine and risperidone improves psychotic-like symptoms during the prodrome. 17, 18 Olanzapine has also been shown to reduce the rate of conversion to psychosis and also delay onset. 18 Combining low-dose risperidone with cognitive behavioural therapy (CBT) has been shown to decrease the rate of transition to psychosis, with a low incidence of adverse effects. 7 Psychological interventions alone (such as CBT) have also been shown to improve symptoms, prevent social decline, and prevent or delay progression to psychosis. In general, patients find psychological interventions more acceptable, tolerable and less stigmatising than taking medication. 19 Currently, we do not have clarity on whether any one of these treatment modalities is more effective than the others.
The acute phase
The acute phase begins in earnest with the onset of florid psychotic symptoms. Acute-phase symptoms include all the symptom domains of schizophrenia, although most attention is focused on positive symptoms. The majority of patients with first-episode psychosis seek help from services during the acute phase, although their illness started in the prodromal phase a few months or even years previously.
Positive symptoms
Delusions, hallucinations and disorganised speech have long been considered the hallmark of schizophrenia. Positive symptoms, however, are not sufficient to warrant the diagnosis of schizophrenia, and may in fact occur in a number of disorders, including mania, substance-induced psychosis and brief psychotic episodes. The DSM-IV-TR criteria for schizophrenia 20 are presented in Table I .
Mood symptoms
Symptoms of depression are common in schizophrenia, and are nearly always a feature of first-episode psychosis. 21 Depressive symptoms are more common during the acute phase, but may occur after the acute phase and are then termed 'post-psychotic depression'. 22 We now know that depressive symptoms differ in their significance, depending on the phase of illness in which they occur. The majority of depressive symptoms in the acute phase resolve after antipsychotic treatment. 22 Their presence in this phase is actually regarded as a positive prognostic factor, as patients with prominent depressive symptoms have fewer negative symptoms and are therefore more likely to have a better outcome. 23 Symptoms of depression that persist beyond the acute phase or that emerge after the acute phase (post-psychotic depression) are, however, associated with a poorer outcome.
These symptoms are not responsive to antipsychotic treatment and therefore require additional interventions. 24 Post-psychotic depression may occur in patients who attribute their illness to loss, humiliation or entrapment. The manner in which patients view the meaning of their psychosis predicts the development of depression. 25 Psychological intervention is thus indicated in these patients, in addition to pharmacological treatment.
It is important to note that patients who suffer from both first- Table I . DSM-IV-TR diagnostic criteria for schizophrenia A. Two or more of the following symptoms present for 1 month: Second-generation immigrants are also at an increased risk of developing schizophrenia. 36 The social defeat theory has been put forward as a possible explanation of this increased risk. Immigrants constantly feel that they are outsiders and are forced into a subordinate role, compared with the dominant population. 35 This perception leads to specific, potentially paranoid thought patterns that may become part of the psychotic illness. Urban upbringing or environment has also been associated with an increased incidence of schizophrenia. 42 Interestingly, it has been shown that urbanisation and genetic factors can act together to increase the risk of schizophrenia, 43 again pointing to the inextricable interaction of genetic vulnerability with environmental factors.
Treatment
Experience of treating schizophrenia has left many clinicians pessimistic about the outcome of the illness. Its long-term outcome has been described as poor; many patients have recurrent relapses, require frequent hospitalisation, and have impairment as the result of negative symptoms, cognitive deterioration and side-effects. 2 Studies of first-episode psychosis patients, however, provide a more optimistic picture. Most first-episode psychosis patients respond to treatment, and more than 80% will remit within 1 year. 44 This good response further supports the critical period for intervention theory, 12 which states that treatment in the first 5 years of illness may limit and even prevent deterioration in social and occupational functioning. It is now evident that the earlier antipsychotics are started, following onset of the illness, the better the response to treatment. 3 Conventional wisdom holds that there is a delay in onset of action of a few weeks in treatment with antipsychotic medication. More recent findings, however, suggest that in fact the majority of the antipsychotic effect takes place within the first week of treatment. 45 Onset of action of antipsychotics has even been shown to occur as early as 24 hours after commencing treatment, with changes apparent on rating scales. 46 First-episode psychosis patients, however, have been shown to have a much more varied response rate. 47 In a study by Emsley et al. many patients responded after only 4 weeks of treatment. Whenever possible, antipsychotic trials should therefore be extended for longer than 1 month in firstepisode patients. 47 In recent years, there has been a great increase in the use of second-generation antipsychotics for the treatment of schizophrenia. Second-generation antipsychotics have been considered superior to typical antipsychotics, as they are less likely to cause extrapyramidal symptoms, 48 and are more effective in treating negative symptoms, mood symptoms and cognitive symptoms of schizophrenia. 49 Two important studies published in the last 2 years have, however, cast some doubts over the superiority of these medications when compared with conventional antipsychotics. Both studies were designed in such a manner as to closely mirror everyday clinical situations 50 and neither was funded by pharmaceutical companies. The CATIE Trial examined the effectiveness of a number of antipsychotics, comparing four second-generation antipsychotics (olanzapine, risperidone, quetiapine and ziprasidone) with perphenazine, a first-generation antipsychotic. 51 The most significant and unintended finding of this study (and a finding that has subsequently received a great deal of attention) was that 74% of subjects discontinued their treatment before the end of the study. This finding has once again highlighted the fact that medication discontinuation remains a major obstacle in the treatment of schizophrenia. Furthermore, the introduction of secondgeneration antipsychotics has not significantly improved medication compliance. 50 The second study (of quality of life in patients with schizophrenia) compared a group on firstgeneration antipsychotics with a group on second-generation antipsychotics. 52 This study found no differences between the two treatment groups and even reported a trend favouring the first-generation antipsychotics.
A further issue relates to the acquisition cost of secondgeneration antipsychotics, which has resulted in only limited availability of these agents in lower-income countries. 
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Although first-episode psychosis patients respond well to treatment, they have a high relapse rate within the first few years of the illness. 57 It now seems likely that, with each relapse, patients are less likely to return to their previous level of functioning. 58 Prevention of relapse therefore becomes a major challenge in the management of first-episode psychosis patients. Since medication discontinuation has been found to be the strongest predictor of relapse, 57 61 There is some evidence that comprehensive programmes are more likely to produce superior outcomes compared with generic mental health services. 62 Therefore, early referral to specialised early psychosis programmes where available, is advisable.
Researchers have also looked at the effectiveness of individual components of psychosocial interventions in firstepisode psychosis. Individual CBT has been shown to be of benefit in reducing symptoms and improving adaptation to the illness and the subjective quality of life, but it has not been effective in reducing relapse rates or re-hospitalisation. 62 Family therapy has, however, been shown to reduce rates of relapse in schizophrenia. 63 Moreover, family work during the first episode has been found to be highly acceptable to family members, as opposed to families of patients who have had multiple relapses. 63 For clinicians working in areas without early psychosis programmes, it is encouraging to note that individual CBT or family therapy is effective and can therefore be used even when specialised units are not available.
Predictors of outcome
Predictors of treatment outcome are relatively well studied, and a large number of factors that can determine outcome in first-episode psychosis have been identified. Male gender, poor obstetric history, severe positive symptoms, poor attention at baseline and the development of parkinsonism during antipsychotic treatment are all predictors of poor outcome. 59 A recent meta-analysis has shown that longer duration of untreated psychosis (DUP) is associated with inferior recovery from first-episode psychosis. 64 Increased DUP has also been found to be associated with a poorer response of negative symptoms. 65 These findings are of particular importance as DUP is one of a few factors that are potentially modifiable, which again emphasises the need for early detection and effective treatment. Recently, researchers have tried to combine baseline clinical features with early treatment response in order to predict accurately which patients will reach remission. 66 They found that by combining neurological soft signs, DUP, marital status, positive and negative syndrome scale (PANSS) excited factor baseline score and early treatment response, they were able to identify accurately which patients will reach remission. This model attempts to make the predictors of outcome variables more clinically useful. 
Conclusion

